Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist Hospital (HMH), will present biomarker data today as part of a presentation at the 2nd Annual Johnson Center Symposium in Houston, TX.
The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and...
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. The US FDA has awarded the SELUTION SLR with four breakthrough designations for coronaries, peripheral vascular and AV Fistula indications.
The study will introduce artificial intelligence technology and cough detection smartphone applications into epidemiological research for the first time.
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Turkish Journal of Emergency Medicine in which Drs. Seda Dağar and Hüseyin Uzunosmanoğlu at the Kecioren Training and Research Hospital in Ankara, Turkey investigated the role that noninvasive, continuous Masimo PVi® might play in monitoring volume status and volume changes in spontaneously breathing patients undergoing hemodialysis (HD).1
The researchers found that there was a “strong correlation” between change in PVi and the volume of fluid removed, concluding...
"The positive outcomes from this five-year study validate the effectiveness and durability of the GORE EXCLUDER Iliac Branch Endoprosthesis for the treatment of iliac artery aneurysms," said Darren B. Schneider, M.D., the study National Principal Investigator and Chief of Vascular Surgery and Endovascular Therapy at Penn Medicine and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. "
Dagi Ben-Noon, Inspira's Chief Executive Officer, stated: "The pump is one of the core components of our ART device. The pump experiment represents an important milestone for us as it enables us to progress to manufacturing phase."
The aim of the study is to assess the feasibility and safety of angioplasty with a sirolimus-eluting balloon in patients with ED and distal internal pudendal and/or penile artery stenotic disease, using Plain Old Balloon (POB) angioplasty as a comparator.
“The data derived from this study are important for a number of reasons,” noted Dr. David G. Armstrong, Professor of Surgery and Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at the Keck School of Medicine of the University of Southern California. Read more.
The 12-month data from PRESTIGE was presented at LINC 2021 in January, showing sustained benefits up to one year. 18-month data is to be presented at VIVA in October this year, where it is anticipated that these benefits will be further sustained.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
